Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SenzaGen ABOSTO:SENZA -0.75%72 Pretax Margin % is -13.81% as of Mar. 2026. GuruFocus rates OSTO:SENZA with a GF Score™ of 72/100 and a GF Value™ of kr6.41 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, SenzaGen AB ranks worse than 64.85% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. SenzaGen AB's Pre-Tax Income for the
three
months ended in Mar. 2026 was kr-2.07 Mil. SenzaGen AB's Revenue for the
three
months ended in Mar. 2026 was kr14.96 Mil. Therefore, SenzaGen AB's pretax margin for the quarter that ended in Mar. 2026 was -13.81%.
The historical rank and industry rank for SenzaGen AB's Pretax Margin % or its related term are showing as below:
OSTO:SENZA'
s Pretax Margin % Range Over the Past 10 Years
Min: -2286.95 Med: -272.39 Max: -20.41
Current: -23.81
OSTO:SENZA's Pretax Margin % is ranked worse than 64.85% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.565
vs OSTO:SENZA: -23.81
SenzaGen AB (OSTO:SENZA) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
SenzaGen AB Pretax Margin % Related Terms
SenzaGen AB Pretax Margin % Historical Data
* Premium members only.
The historical data trend for SenzaGen AB's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SENZA vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, SenzaGen AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SenzaGen AB Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SenzaGen AB's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where SenzaGen AB's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SenzaGen AB (OSTO:SENZA) has a Pretax Margin % of -13.81% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on SenzaGen AB and its competitors. According to the industry distribution chart, SenzaGen AB ranks #131 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 64.9%.
Is SenzaGen AB's Pretax Margin % too high?
SenzaGen AB's current Pretax Margin % is -13.81%. Based on the distribution chart, SenzaGen AB ranks #131 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, SenzaGen AB has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SenzaGen AB's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SenzaGen AB ranks #131 out of 202 companies for Pretax Margin %. This places SenzaGen AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on SenzaGen AB and its competitors. SenzaGen AB's current Pretax Margin % is -13.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SenzaGen AB stock overvalued right now?
Based on GuruFocus' analysis, SenzaGen AB (OSTO:SENZA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr6.41, compared to a current price of kr5.30 — trading 17.3% below its estimated fair value. The current Pretax Margin % is -13.81%. SenzaGen AB's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For SenzaGen AB (OSTO:SENZA), the current Pretax Margin % is -13.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SenzaGen AB (OSTO:SENZA) Overvalued in 2026?
Based on GuruFocus' analysis, SenzaGen AB stock appears to be undervalued.
The current stock price of kr5.30 is trading 17.3% below its estimated GF Value™ of kr6.41.
GuruFocus considers SenzaGen AB to be Modestly Undervalued.
Key valuation signals for OSTO:SENZA:
Pretax Margin %: -13.81%
GF Value™: kr6.41 vs. price of kr5.30 (17.3% below fair value)
No single metric tells the full story. See the OSTO:SENZA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SenzaGen AB markets, sells, and performs in vitro testing using its Genomic Allergen Rapid Detection (GARD) platform through its laboratory and a network of contract research organizations. The company provides animal-free testing solutions for chemical compounds used in industries such as cosmetics, chemicals, pharmaceuticals, medical devices, and food and nutrition. Geographically, it operates in the Americas, EMEA, and APAC, with the majority of revenue from EMEA.
72GF Score
Get the complete analysis for OSTO:SENZA
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SENZA has been successfully added to your 
